ScinoPharm Taiwan Ltd
TWSE:1789
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.35
28.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| TW |
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
20.2B TWD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
| Min | -21 347.1% |
| 30th Percentile | 0.7% |
| Median | 5% |
| 70th Percentile | 11.5% |
| Max | 698% |
Other Profitability Ratios
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ScinoPharm Taiwan Ltd is 5.2%, which is below its 3-year median of 9.7%.
Over the last 3 years, ScinoPharm Taiwan Ltd’s Operating Margin has decreased from 11.5% to 5.2%. During this period, it reached a low of 5.2% on Oct 30, 2025 and a high of 12.9% on Jun 30, 2024.